Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05238792 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors

Study acronym: ATTACK
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
Enrollment reduced 33% 36 → 24 participants
See other at-risk trials from Children's National Research Institute

Record History

  1. Primary endpoint(s) modified Enrollment reduced: 36 → 24 participants · Trial arms changed: 2 → 1 · Eligibility criteria expanded, about 22 words · 2 morev6 Show 5 more changesShow less
    • Enrollment reduced: 36 → 24 participants
    • Trial arms changed: 2 → 1
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoint revised
    • Study description shortened, about 257 words

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Oct 2025 to Oct 2028 Completion date: Oct 2027 to Oct 2029 · Site contact updatedv5 Show 2 more changesShow less
    • Completion date: Oct 2027 to Oct 2029
    • Site contact updated
  3. Site contact updatedv4
  4. Re-verified, no change to tracked fieldsv3
  5. Eligibility criteria expanded, about 1 word Study description shortened, about 1 wordv2 Show 1 more changeShow less
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label phase I dose-escalation study to evaluate the safety of partially human leukocyte antigen (HLA)-matched multi tumor-associated antigen-specific T cell (TAA-T) therapy following lymphodepleting conditioning with or without local tumor ablation for pediatric and adult patients with high-risk solid tumors due to the presence of refractory, relapsed and/or minimal residual detectable disease following conventional therapy (e.g., chemotherapy, surgery, radiation, autologous stem cell transplant, or targeted therapy).
Trial Details
NCT Number NCT05238792
Lead Sponsor Children's National Research Institute
Conditions Solid Tumor
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov